RemeGen Co. (9995.HK) climbed 5% during Hong Kong trading to HK$81.85.

The rally tracked a broader biotech rally after Moderna and Merck reported positive Phase 3 results for their personalized mRNA cancer vaccine, lifting Hong Kong-listed biotech names. RemeGen's expected first-half net profit of roughly 4.7 billion yuan, driven largely by the upfront payment from the RC148 licensing deal, also underpinned sentiment.